ATRA · Atara Biotherapeutics, Inc. · Executive Compensation
$9.16
+0.20 (+2.23%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our existing cash, cash equivalents and short-term investments as of June 30, 2026 will not be sufficient to fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. These conditions raise substantial doubt about our ability to continue as a going concern for at least 12 months after the issuance of the accompanying condensed consolidated financial statements.”View the 10-Q filed Aug 12, 2026
Market Cap
$93.25M
Shares
10.04M
Volume · Oct 20
14.85K
Avg daily vol (3M)
45.84K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. Former President and Chief Executive Officer | $1,722,332 |
| AnhCo Nguyen | President and Chief Executive Officer | $1,573,716 |
| Eric Hyllengren | Former EVP, Chief Financial Officer and Chief Operating Officer | $926,137 |
| Amar Murugan | Former EVP, Chief Legal Officer | $878,428 |
| Jill Henrich | Former EVP, Chief Regulatory Officer | $812,547 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. Former President and Chief Executive Officer | $4,375,125 |
| Amar Murugan | Former EVP, Chief Legal Officer | $2,312,153 |
| AnhCo Nguyen | President and Chief Executive Officer | $2,277,691 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. | $5,158,127 |
| Charlene Banard | EVP, Chief Technical Officer | $3,201,748 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. | $5,117,335 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. | $5,285,827 |
| Jakob Dupont | EVP, Global Head of Research and Development | $2,796,245 |
| Kristin Yarema | SVP, Chief Commercial Officer | $2,436,407 |
| Joseph Newell | EVP, Chief Operations Officer | $2,251,063 |
| Utpal Koppikar | Chief Financial Officer | $2,137,953 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Pascal Touchon | D.V.M. President & Chief Executive Officer | $6,637,307 |
| Joseph Newell | EVP, Chief Operations Officer | $2,719,167 |
| Utpal Koppikar | Chief Financial Officer | $2,540,170 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Isaac Ciechanover M.D | Former President & Chief Executive Officer | $6,132,757 |
| Dietmar Berger | M.D., Ph.D. Former Global Head of Research & Development | $4,972,439 |
| Utpal Koppikar | Chief Financial Officer | $4,220,282 |
| Mina Kim | Former SVP, Corporate Strategy and General Counsel | $3,384,425 |
| Joseph Newell | EVP, Chief Operations Officer | $2,492,292 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Joseph Newell | EVP, Chief Technical Operations Officer | $1,815,798 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kevin G. Sarney | interim chief financial officer | Appointed | 2026-06-26 |
| Yanina Grant-Huerta | Chief Accounting Officer | Terminated | 2026-06-26 |
| Brian Cherry | Class I director | Appointed | 2026-06-12 |
| Maria Grazia Roncarolo, M.D. | director | Resigned | 2025-09-04 |
| Pascal Touchon | director | Resigned | 2025-09-04 |
| Ameet Mallik | director | Resigned | 2025-09-04 |
| Nachi Subramanian | member of the Board | Appointed | 2025-05-15 |
| James Huang | member of the Board | Appointed | 2025-05-15 |
| Yanina Grant-Huerta | Chief Accounting Officer | Appointed | 2025-03-31 |
| Eric Hyllengren | Chief Operating Officer | Appointed | 2024-11-12 |
| Greg Ciongoli | Board of Directors | Appointed | 2024-11-12 |
| Pascal Touchon | Chairman of the Board of Directors | Appointed | 2024-11-12 |
| Cokey Nguyen | President and CEO | Appointed | 2024-11-12 |
| Amar Murugan | Chief Legal Officer | Terminated | 2024-11-12 |
| Eric Hyllengren | Chief Operating Officer | Appointed | 2024-10-15 |
| Gregory A. Ciongoli | Board of Directors | Appointed | 2024-09-03 |
| Gregory A. Ciongoli | member of the Board | Appointed | 2024-09-03 |
| Carol Gallagher, Pharm.D. | Independent Lead Director | Appointed | 2024-08-12 |
| Cokey Nguyen, Ph.D. | Board of Directors | Appointed | 2024-08-12 |
| Cokey Nguyen, Ph.D. | President and CEO | Appointed | 2024-08-12 |
| AnhCo "Cokey" Thieu Nguyen | President and Chief Executive Officer | Appointed | 2024-08-12 |
| AnhCo Nguyen | member of the Board | Appointed | 2024-08-12 |
| AnhCo Nguyen | President and Chief Executive Officer | Appointed | 2024-08-12 |
| Pascal Touchon | Chairman of the Board | Appointed | 2024-08-12 |
| Pascal Touchon | President and Chief Executive Officer | Resigned | 2024-08-12 |
Leadership
- AnhCo "Cokey" Thieu Nguyen CEO
- AnhCo Nguyen CEO, Board Member
- Cokey Nguyen CEO
- Cokey Nguyen, Ph.D. CEO, Board Member
- Isaac Ciechanover M.D CEO
- Carol D. Gallagher, Pharm D. Chairman
- Gregory A. Ciongoli Chairman, Board Member
- Pascal Touchon Chairman
- Ron Renaud Chairman, Board Member
- Eric Hyllengren CFO, COO
- Kevin G. Sarney CFO
- Amar Murugan General Counsel
- Yanina Grant-Huerta Chief Accounting Officer
- Brian Cherry Board Member
- Carol Gallagher, Pharm.D. Board Member
- Dr. Maria Grazia Roncarolo Board Member
- Greg Ciongoli Board Member
- James Huang Board Member
- Maria Grazia Roncarolo, M.D. Board Member
- Nachi Subramanian Board Member
- Pascal Touchon, D.V.M. Board Member